Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
View Patent ↗Compounds represented by the formula: A is (CH 2 ) n R 2 , —CH═CH 2 , CH 2 —CH═CH 2 , O(CH 2 ) n R 2 , CH(OH)CH 3 , CH(OH)CH 2 OH, CH 2 —CH(OH)CH 3 , CH 2 CH(OH)CH 2 OH, or CH(OH)CH(OH)CH 3 , R,R 1 individually is H, NH 2 OH, Cl, Br, I, aryl, substituted aryl, heterocycle, NR 3 R 4 , OR 3 or SR 3 , R 2 is H, OH, F, N 3 , NH 2 , CO 2 H, SH, alkyl, substituted alkyl, S-alkyl, O-acyl, CONH 2 , or CONH-alkyl, n is 1-3, y is O, S or NH, W is O or S, Z, Z′ individually is OR 3 , OR 4 , O(CH 2 ) m —O—(CH 2 ) x CH 3 , NH—CH(alkyl)CO 2 R 3 , alkyl, substituted alkyl, OCH 2 CH 2 S—C(O)CH 3 , OCH 2 CH 2 S—C(O)CH(CH 3 ) 2 , OCH 2 CH 2 S—C(O)C(CH 3 ) 3 , OCH 2 CH 2 —SC(O)aryl, OCH 2 CH 2 —S—S—OCH 2 CH 2 OH, OCH 2 OC(O)C(CH 3 ) 3 , OCH 2 —O—C(O)OCH(CH 3 ) 2 , or OCH 2 —O—C(O)CH(CH 3 ) 2 R 3 , R 4 individually is H, alkyl, substituted alkyl, aryl, or substituted aryl; Both R 3 and R 4 can form a monocyclic ring of 4-7 atoms with N or optionally a further heteroatom in the ring; m is 1-3, x is 0-19; and pharmaceutically acceptable salts thereof and prodrugs thereof are provided.
1. A compound represented by the formula:
wherein A is selected from the group consisting of (CH 2 ) n R 2 , —CH═CH 2 , CH 2 —CH═CH 2 , O(CH 2 ) n R 2 , CH(OH)CH 3 , CH(OH)CH 2 OH, CH 2 —CH(OH)CH 3 , and CH 2 CH(OH)CH 2 OH, CH(OH)CH(OH)CH 3 ,
R is selected from the group consisting of, aryl, substituted aryl, heterocycle, NR 3 R 4 , and OR 3 , provided that both R and R 1 cannot both be OR 3 ,
R 1 is selected from the group consisting of H, Cl, Br, I, aryl, substituted aryl, heterocycle, NR 3 R 4 , OR 3 , and SR 3 ,
R 2 is selected from the group consisting of H, OH, F, N 3 , NH 2 , CO 2 H, SH, alkyl, substituted alkyl, S-alkyl, O-acyl, CONH 2 , and CONH-alkyl,
n is an integer of 1-3,
y is selected from the group consisting of O, S and NH,
W is selected from the group consisting of O and S,
Z and Z′ are individually selected from the group consisting of O(CH 2 ) m —O—(CH 2 ) x CH 3 , NH—CH(alkyl)CO 2 R 3 , alkyl, substituted alkyl, OCH 2 CH 2 S—C(O)CH 3 , OCH 2 CH 2 S—C(O)CH(CH 3 ) 2 , OCH 2 CH 2 S—C(O)C(CH 3 ) 3 , OCH 2 CH 2 —SC(O)aryl, OCH 2 CH 2 —S—S—OCH 2 CH 2 OH, OCH 2 OC(O)C(CH 3 ) 3 , OCH 2 —O—C(O)OCH(CH 3 ) 2 , and OCH 2 —O—C(O)CH(CH 3 ) 2 ,
R 3 and R 4 are individually selected from the group consisting of H, alkyl, substituted alkyl, aryl, and substituted aryl; additionally, R 3 and R 4 of NR 3 R 4 can form a monocyclic ring of 4-7 atoms with N or optionally a further heteroatom in the ring,
m is an integer of 1-3,
x is an integer of 0-19;
and pharmaceutically acceptable salts thereof and prodrugs thereof.
2. The compound according to claim 1 represented by the formula:
A is selected from the group consisting of CH 2 OH, CH 2 OCH 3 , CH 2 N 3 , CH 2 NH 2 , CH(OH)CH 3 , CH 2 F, and CH 2 CH 2 OH,
Z and Z′ individually is selected from the group consisting of O(CH 2 ) m —O—(CH 2 ) x CH 3 , NH—CH(alkyl)CO 2 R 3 , alkyl, substituted alkyl, OCH 2 CH 2 S—C(O)CH 3 , OCH 2 CH 2 S—C(O)CH(CH 3 ) 2 , OCH 2 CH 2 S—C(O)C(CH 3 ) 3 , OCH 2 CH 2 —SC(O) aryl, OCH 2 CH 2 —S—S—OCH 2 CH 2 OH, OCH 2 OC(O)C(CH 3 ) 3 , OCH 2 —O—C(O)OCH(CH 3 ) 2 , and OCH 2 —O—C(O)CH(CH 3 ) 2 ,
R 3 is selected from the group consisting of H, alkyl, substituted alkyl, aryl, and substituted aryl,
m is an integer of 1-3,
x is an integer of 0-19;
and pharmaceutically acceptable salts thereof and prodrugs thereof.
3. The compound according to claim 1 represented by the formula:
A is selected from the group consisting of CH 2 OH, CH 2 N 3 , CH 2 NH 2 , CH 2 OCH 3 , CH 3 , and CH(OH)CH 3 ,
Z and Z′ are individually selected from the group consisting of O(CH 2 ) m —O—(CH 2 ) x CH 3 , NH—CH(alkyl)CO 2 R 3 , alkyl, substituted alkyl, OCH 2 CH 2 S—C(O)CH 3 , OCH 2 CH 2 S—C(O)CH(CH 3 ) 2 , OCH 2 CH 2 S—C(O)C(CH 3 ) 3 , OCH 2 CH 2 —SC(O) aryl, OCH 2 CH 2 —S—S—OCH 2 CH 2 OH, OCH 2 OC(O)C(CH 3 ) 3 , OCH 2 —O—C(O)OCH(CH 3 ) 2 , and OCH 2 —O—C(O)CH(CH 3 ) 2 ,
R 3 is selected from the group consisting of H, alkyl, substituted alkyl, aryl, and substituted aryl,
m is an integer of 1-3,
x is an integer of 0-19;
and pharmaceutically acceptable salts thereof and prodrugs thereof.
4. The compound according to claim 2 represented by the formula:
A is selected from the group consisting of CH 2 OH, CH 2 OCH 3 , CH 2 N 3 , CH 2 NH 2 , CH(OH)CH 3 , CH 2 F, and CH 2 CH 2 OH,
Z and Z′ individually is selected from the group consisting of —O—CH 2 OC(O)C(CH 3 ) 3 , —O—CH 2 OC(O)OCH(CH 3 ) 2 ;
and pharmaceutically acceptable salts thereof and prodrugs thereof.
5. The compound according to claim 3 represented by the formula:
A is selected from the group consisting of CH 2 OH, CH 2 N 3 , CH 2 NH 2 , CH 2 OCH 3 , CH 3 , and CH(OH)CH 3
Z and Z′ individually is selected from the group consisting of —O—CH 2 —OC(O)C(CH 3 ) 2 , and OCH 2 OC(O)OCH(CH 3 ) 2 ;
and pharmaceutically acceptable salts thereof and prodrugs thereof.
6. The compound represented by the formula:
Z and Z′ individually is selected from the group consisting of OR 3 , OR 1 , O(CH 2 ) m —O—(CH 2 ) x CH 3 , NH—CH(alkyl)CO 2 R 3 , alkyl, substituted alkyl, OCH 2 CH 2 S—C(O)CH 3 , OCH 2 CH 2 S—C(O)CH(CH 3 ) 2 , OCH 2 CH 2 S—C(O)C(CH 3 ) 3 , OCH 2 CH 2 —SC(O) aryl, OCH 2 CH 2 —S—S—OCH 2 CH 2 OH, OCH 2 OC(O)C(CH 3 ) 3 , OCH 2 —O—C(O)OCH(CH 3 ) 2 , and OCH 2 —O—C(O)CH(CH 3 ) 2
R 3 and R 4 is selected from the group consisting of H, alkyl, substituted alkyl, aryl, and substituted aryl,
m is an integer of 1-3,
x is an integer of 0-19;
and pharmaceutically acceptable salts thereof and prodrugs thereof.
7. The compound according to claim 6 represented by the formula:
Z and Z′ is selected from the group consisting of OH, —O—CH 2 OC(O)C(CH 3 ) 3 , and —OCH 2 OC(O)OCH(CH 3 ) 2 ,
and pharmaceutically acceptable salts thereof and prodrugs thereof.
8. The compound represented by the formula:
Z and Z′ is selected from the group consisting of OH, —O—CH 2 OC(O)C(CH 3 ) 3 , and —OCH 2 OC(O)OCH(CH 3 ) 2 ;
and pharmaceutically acceptable salts thereof and prodrugs thereof.
9. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
10. A method for inhibiting HCV polymerase in a patient by administering to the patient at least one compound according to claim 1 .
11. A method for treating a patient suffering from HCV which comprises administering to said patient an effective amount of at least one compound according to claim 1 .
12. A method for inhibiting in a patient in need thereof a HCV viral polymerase which comprises administering to said patient an effective amount of at least one compound according to claim 1 and at least one further therapeutic agent from the group consisting of interferon (IFN), interferon α-2a, interferon α-2b, consensus interferon (CIFN), ribavirin, amantadine, rimantadine, interleukine-12, ursodeoxycholic acid (UDCA), and glycyrrhizin.
13. A method for treating a patient suffering from a HCV viral infection which comprises administering to the patient an effective amount of at least one compound according to claim 1 and at least one further therapeutic agent chosen from interferon (IFN), interferon α-2a, interferon α-2b, consensus interferon (CIFN), ribavirin, amantadine, rimantadine, interleukine-12, ursodeoxycholic acid (UDCA), and glycyrrhizin.
14. A pharmaceutical composition comprising a compound according to claim 3 and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising a compound according to claim 6 and a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising a compound according to claim 8 and a pharmaceutically acceptable carrier.